260 related articles for article (PubMed ID: 27894956)
1. Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
Kim JY; Lee N; Kim YJ; Cho Y; An H; Oh E; Cho TM; Sung D; Seo JH
Cancer Lett; 2017 Feb; 386():151-160. PubMed ID: 27894956
[TBL] [Abstract][Full Text] [Related]
2. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
[TBL] [Abstract][Full Text] [Related]
5. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
6. Combination of the 6-thioguanine and disulfiram/Cu synergistically inhibits proliferation of triple-negative breast cancer cells by enhancing DNA damage and disrupting DNA damage checkpoint.
Chu M; An X; Zhang D; Li Q; Dai X; Yu H; Li Z
Biochim Biophys Acta Mol Cell Res; 2022 Feb; 1869(2):119169. PubMed ID: 34763028
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
8. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.
Wu X; Xue X; Wang L; Wang W; Han J; Sun X; Zhang H; Liu Y; Che X; Yang J; Wu C
Eur J Pharmacol; 2018 May; 827():1-12. PubMed ID: 29547841
[TBL] [Abstract][Full Text] [Related]
9. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
10. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
Gari HH; DeGala GD; Ray R; Lucia MS; Lambert JR
Cancer Lett; 2016 Oct; 380(2):505-512. PubMed ID: 27452906
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
[TBL] [Abstract][Full Text] [Related]
12. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
14. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas.
Li Y; Fu SY; Wang LH; Wang FY; Wang NN; Cao Q; Wang YT; Yang JY; Wu CF
Cancer Lett; 2015 Dec; 369(1):86-96. PubMed ID: 26254539
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
16. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel.
Xu X; Xu J; Zhao C; Hou X; Li M; Wang L; Chen L; Chen Y; Zhu L; Yang H
Biomed Pharmacother; 2019 Dec; 120():109529. PubMed ID: 31606620
[TBL] [Abstract][Full Text] [Related]
18. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram/copper shows potent cytotoxic effects on myelodysplastic syndromes via inducing Bip-mediated apoptosis and suppressing autophagy.
Zha J; Bi S; Deng M; Chen K; Shi P; Feng L; He J; Pu X; Guo C; Zhao H; Li Z; Jiang Y; Song H; Xu B
Eur J Pharmacol; 2021 Jul; 902():174107. PubMed ID: 33865831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]